ClinicalTrials.gg
CompletedNCT05518123Updated May 22, 2026Results posted

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

A Phase 4 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 111 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
962
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
10th of 32
962 · median 618
Started
2022
with 7 others
Phase 4
9 of 32
4 open now
Registered
18th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 10th largest by enrollment, is one of 8 that started in 2022, is one of 9 in phase 4, and was the 18th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications

03

Conditions studied

  • Migraine

Keywords

  • Migraine Prevention
  • Headache
  • Headache Prevention
  • Migraine Prevention in adults with inadequate response to oral preventative medications
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
  2. Migraine attacks, on average, lasting about 4 - 72 hours, if untreated.
  3. 4 to 14 migraine days per month, on average, across the 3 months prior to the Screening Visit (month is defined as 28-days for the purpose of this protocol).
  4. Less than15 headache days (migraine or non-migraine) per month in each of the 3-months prior to the Screening Visit and throughout the Screening Phase.
  5. Subjects must be able to distinguish migraine attacks from tension/cluster headaches. Prior inadequate response, within 10 years of the Screening Visit, to agents across 2-4 categories of recognized, orally-administered, migraine-preventive medications where at least one example of prior inadequate response is due to lack of efficacy or prior intolerance (not ).

Exclusion criteria

Exclusion Criteria:

  1. History of cluster headaches, basilar migraine (migraine with brainstem aura), or hemiplegic migraine.
  2. Current medication overuse headaches.
  3. 15 or more headache days (migraine or non-migraine) per month in any of the 3-months prior to the Screening Visit or during the first 28- days of the Observation Phase.
  4. Inadequate response (due to lack of efficacy, prior intolerance, or ) to agents across > 4 categories of recognized, orally administered, migraine-preventive medications.
  5. Active chronic pain syndrome (such as fibromyalgia, chronic pelvic pain, complex regional pain syndrome [CRPS]).
  6. Other pain syndromes (including trigeminal neuralgia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, interfere with study assessments of safety or efficacy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
962 participants (actual)

Study arms

  • Experimental
    Rimegepant 75 mg

    Drug: Rimegepant

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase

  • DrugPlacebo

    Matching placebo with every other day dosing during DBT phase

06

What researchers measure

Primary outcomes

  1. Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

    A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.

    Time frame: Observation phase (28 days prior to randomization), DBT phase (through Month 3 [Week 1 to 12])

Secondary outcomes

  1. Percentage of Participants With >= 50 Percent (%) Reduction From OP in the Number of Moderate or Severe Migraine Days (MD) Per Month Over the Entire DBT Phase (Weeks 1 to 12)

    Moderate or severe MD: a MD of moderate or severe headache pain intensity. MD: any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. Qualified migraine headache: migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of moderate or severe MD per month were prorated to 28 days and derived from data in the on-DBT efficacy analysis period as follows: 28\*(total number of moderate or severe MD through Month 3 \[Weeks 1 to 12\])/(total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).

    Time frame: DBT phase (through Month 3 [Week 1 to 12])

  2. Mean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase

    A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.

    Time frame: Observation phase (28 days prior to randomization), Week 1 to Week 4 of the DBT phase

  3. Mean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase

    A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.

    Time frame: Observation phase (28 days prior to randomization), Week 9 to Week 12 of the DBT phase

  4. Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase

    MSQ version 2.1 was a self-administered, 14-item instrument validated in 3 domains: role function-restrictive (7 items), role function-preventive (4 items), emotional function (3 items). The restrictive role function domain consisted of 7 items that described how migraine limited one's daily social and work-related activities. Each item was scored on a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw dimension scores for restrictive role function domain were computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.

    Time frame: Baseline (Day 1) and Week 12 of the DBT phase

  5. Mean Change From Baseline in the Migraine Interictal Burden Scale (MIBS) Score at Week 12 of the DBT Phase

    MIBS was a 4-item self-administered questionnaire that measures: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Each item was rated on a 6-point scale as: don't know/ not applicable; never; rarely; some of the time; much of the time; most or all of the time. The MIBS score was the weighted sum of the item scores and ranged from 0 to 12. Higher scores indicated a greater impact of headaches on the participant's life between headache attacks.

    Time frame: Baseline (Day 1) and Week 12

  6. Number of Participants With Any Adverse Events (AEs) by Worst Intensity in the DBT Phase.

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AE intensity included mild, moderate and severe, where Mild: usually transient and required only minimal treatment or therapeutic intervention. Event did not generally interfere with usual activities of daily living. Moderate: usually alleviated with additional specific therapeutic intervention. Event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to participant. Severe: interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Participants were counted once in each intensity category based on greatest intensity of unique adverse event preferred terms.

    Time frame: DBT Phase: From Day 1 to Week 12

  7. Number of Participants With Any AEs by Worst Intensity in the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AE intensity included mild, moderate and severe, where Mild: usually transient and required only minimal treatment or therapeutic intervention. Event did not generally interfere with usual activities of daily living. Moderate: usually alleviated with additional specific therapeutic intervention. Event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to participant. Severe: interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Participants were counted once in each intensity category based on greatest intensity of unique adverse event preferred terms.

    Time frame: OLE Phase: From Week 12 to Week 24

  8. Number of Participants With Serious AEs (SAEs) in the DBT Phase

    A serious adverse event (SAE) was any event that met any of the following criteria at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant and other important medical events.

    Time frame: DBT Phase: From Day 1 to Week 12

  9. Number of Participants With SAEs in the OLE Phase

    A SAE was any event that met any of the following criteria at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant and other important medical events.

    Time frame: OLE Phase: From Week 12 to Week 24

  10. Number of Participants With AEs Leading to Study Drug Discontinuation in the DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with AEs leading to discontinuation of study drug were reported.

    Time frame: DBT Phase: From Day 1 to Week 12

  11. Number of Participants With AEs Leading to Study Drug Discontinuation in the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with AEs leading to discontinuation of study drug were reported.

    Time frame: OLE Phase: From Week 12 to Week 24

  12. Number of Participants With Grade 3 to 4 Laboratory Abnormalities: DBT Phase

    Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1. Only those Grade 3 or 4 laboratory tests with non-zero values in any of treatment arms are reported in this outcome measure.

    Time frame: DBT Phase: From Day 1 to Week 12

  13. Number of Participants With Grade 3 to 4 Laboratory Abnormalities: OLE Phase

    Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to NCI CTCAE v5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1. Only those Grade 3 or 4 laboratory tests with non-zero values in any of treatment arms are reported in this outcome measure.

    Time frame: OLE Phase: From Week 12 to Week 24

  14. Percentage of Participants With >= 50% Reduction From OP in the Number of Migraine Days Per Month (Regardless of Pain Intensity) Over the Entire DBT Phase (Weeks 1 to 12)

    A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days and derived from data in the on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\])/(total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).

    Time frame: DBT phase (through Month 3 [Week 1 to 12])

  15. Mean Number of Acute Migraine-Specific Medication Days Per Month in Each Month and Over the Entire DBT Phase (Weeks 1 to 12)

    An acute migraine-specific medication day was defined as any calendar day during which a participant took a migraine-specific acute migraine medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. The number of acute migraine-specific medication days per month were prorated to 28 days.

    Time frame: DBT phase Months 1, 2 and 3; overall DBT through Month 3 (Week 1 to 12)

  16. Mean Change From Baseline in MIBS Scores at Weeks 4, 8, and 12 in the DBT Phase

    MIBS was a 4-item self-administered questionnaire that measures: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Each item was rated on a 6-point scale as: don't know/ not applicable; never; rarely; some of the time; much of the time; most or all of the time. The MIBS score was the weighted sum of the item scores and ranged from 0 to 12. Higher scores indicated a greater impact of headaches on the participant's life between headache attacks.

    Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12

  17. Mean Change From Baseline in MSQ Domain Scores at Weeks 4, 8, and 12 in the DBT Phase

    MSQ was a self-administered, 14-item instrument validated in 3 domains: role function-restrictive (7 items), role function-preventive (4 items), emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw domain scores are computed as a sum of item responses and rescaled to a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.

    Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12

  18. Mean Change From Baseline in Migraine Functional Impact Questionnaire (MFIQ) Domain Scores in Each Month of the DBT Phase

    MFIQ was a 26-item participant-report questionnaire. It is designed to measure the subjective impact of migraine on physical, social, and emotional functioning over 5 domains: physical function (5 items), usual activities (10 items), social function (5 items), emotional function (5 items) and overall impact on usual activities (16 items). Participants responded to items using a 5-point scale assigned scores from 1 to 5, with 5 representing the greatest burden. Each domain score was calculated as the sum of the item responses and rescaled to a 0 to 100 scale, with higher scores representing greater burden. The recall period was the past 7 days.

    Time frame: DBT Phase: Baseline (Day 1), Months 1, 2, and 3

  19. Change From Baseline in Work Productivity and Activity Impairment (WPAI) - Migraine Absenteeism Scores at Weeks 4, 8, and 12 in the DBT Phase

    The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The absenteeism score was calculated from Q2 and Q4 for participants who responded "yes" to Q1 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.

    Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12

  20. Change From Baseline in WPAI - Migraine Presenteeism Scores at Weeks 4, 8, and 12 in the DBT Phase

    The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The presenteeism score was calculated using Q5 for participants who responded "yes" to Q1 and had Q4\>0 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.

    Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12

  21. Change From Baseline in WPAI - Migraine Work Productivity Loss Scores at Weeks 4, 8, and 12 in the DBT Phase

    The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The work productivity loss score was calculated using Q2, Q4, and Q5 for participants who responded "yes" to Q1 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.

    Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12

  22. Change From Baseline in WPAI - Migraine Activity Impairment Scores at Weeks 4, 8, and 12 in the DBT Phase

    The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The activity impairment score was calculated using Q6 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.

    Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12

  23. Mean Change From Baseline in Patient Global Assessment (PGA) Score in Each Month of the DBT Phase

    The PGA scale was a single item assessment that measured the participant's overall assessment of migraine on a 5-point scale as: (1) very good: asymptomatic and no limitation of normal activities; (2) good: mild symptoms and no limitation of normal activities; (3) fair: moderate symptoms and limitation of some normal activities; (4) poor: severe symptoms and inability to carry out most normal activities; (5) very poor: very severe symptoms which are intolerable and inability to carry out all normal activities. Lower scores indicated fewer symptoms and less disability to carry out normal activities.

    Time frame: DBT Phase: Baseline (Day 1), Months 1, 2, and 3

07

Results

Posted May 22, 2026

Participant flow

DBT Phase
Participant flow — DBT Phase
MilestoneDouble Blind (DB) Rimegepant/ Open Label (OL) RimegepantDB Placebo/ OL Rimegepant
Started330328
Treated328324
Completed316308
Not completed1420
Withdrew: Adverse event53
Withdrew: Lost to follow-up10
Withdrew: Non-compliance (with study drug)01
Withdrew: Other12
Withdrew: Protocol violation04
Withdrew: Withdrawal of consent710
OLE Phase
Participant flow — OLE Phase
MilestoneDouble Blind (DB) Rimegepant/ Open Label (OL) RimegepantDB Placebo/ OL Rimegepant
Started301294
Completed292280
Not completed914
Withdrew: Adverse event42
Withdrew: Lost to follow-up12
Withdrew: Non-compliance (with study drug)01
Withdrew: Other03
Withdrew: Protocol violation10
Withdrew: Withdrawal of consent36

Outcome measures

PrimaryMean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.

Time frame:
Observation phase (28 days prior to randomization), DBT phase (through Month 3 [Week 1 to 12])
Reported as:
Least squares mean · Migraine Days per month
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Migraine Days per monthDB RimegepantDB Placebo
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)-2.1 (-2.47 to -1.74)-0.5 (-0.82 to -0.11)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Mixed Models Analysis · p = <0.0001 · Least square mean (lsm) difference: -1.6 · 95% CI -2.13 to -1.15
SecondaryPercentage of Participants With >= 50 Percent (%) Reduction From OP in the Number of Moderate or Severe Migraine Days (MD) Per Month Over the Entire DBT Phase (Weeks 1 to 12)

Moderate or severe MD: a MD of moderate or severe headache pain intensity. MD: any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. Qualified migraine headache: migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of moderate or severe MD per month were prorated to 28 days and derived from data in the on-DBT efficacy analysis period as follows: 28\*(total number of moderate or severe MD through Month 3 \[Weeks 1 to 12\])/(total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).

Time frame:
DBT phase (through Month 3 [Week 1 to 12])
Reported as:
Number · Percentage of participants
Percentage of Participants With >= 50 Percent (%) Reduction From OP in the Number of Moderate or Severe Migraine Days (MD) Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With >= 50 Percent (%) Reduction From OP in the Number of Moderate or Severe Migraine Days (MD) Per Month Over the Entire DBT Phase (Weeks 1 to 12)34.0 (28.8 to 39.1)13.8 (10.0 to 17.6)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Mantel Haenszel · p = <0.0001 (Tested in hierarchical order) · Difference in percentage: 20.1 · 95% CI 13.7 to 26.5
SecondaryMean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase

A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.

Time frame:
Observation phase (28 days prior to randomization), Week 1 to Week 4 of the DBT phase
Reported as:
Least squares mean · Migraine Days per month
Mean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase
Migraine Days per monthDB RimegepantDB Placebo
Mean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase-1.8 (-2.20 to -1.38)-0.1 (-0.45 to 0.29)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Mixed Models Analysis · p = <0.0001 (Tested in hierarchical order) · Lsm difference: -1.7 · 95% CI -2.25 to -1.17
SecondaryMean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase

A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.

Time frame:
Observation phase (28 days prior to randomization), Week 9 to Week 12 of the DBT phase
Reported as:
Least squares mean · Migraine Days per month
Mean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase
Migraine Days per monthDB RimegepantDB Placebo
Mean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase-2.3 (-2.72 to -1.85)-0.9 (-1.32 to -0.39)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Mixed Models Analysis · p = <0.0001 (Tested in hierarchical order) · Lsm difference: -1.4 · 95% CI -2.05 to -0.80
SecondaryMean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase

MSQ version 2.1 was a self-administered, 14-item instrument validated in 3 domains: role function-restrictive (7 items), role function-preventive (4 items), emotional function (3 items). The restrictive role function domain consisted of 7 items that described how migraine limited one's daily social and work-related activities. Each item was scored on a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw dimension scores for restrictive role function domain were computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.

Time frame:
Baseline (Day 1) and Week 12 of the DBT phase
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase
Units on a scaleDB RimegepantDB Placebo
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase21.1 (18.95 to 23.35)14.6 (12.48 to 16.68)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Mixed Models Analysis · p = <0.0001 (Tested in hierarchal order) · Lsm difference: 6.6 · 95% CI 3.60 to 9.54
SecondaryMean Change From Baseline in the Migraine Interictal Burden Scale (MIBS) Score at Week 12 of the DBT Phase

MIBS was a 4-item self-administered questionnaire that measures: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Each item was rated on a 6-point scale as: don't know/ not applicable; never; rarely; some of the time; much of the time; most or all of the time. The MIBS score was the weighted sum of the item scores and ranged from 0 to 12. Higher scores indicated a greater impact of headaches on the participant's life between headache attacks.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in the Migraine Interictal Burden Scale (MIBS) Score at Week 12 of the DBT Phase
Units on a scaleDB RimegepantDB Placebo
Mean Change From Baseline in the Migraine Interictal Burden Scale (MIBS) Score at Week 12 of the DBT Phase-1.9 (-2.24 to -1.52)-1.0 (-1.36 to -0.67)
Statistical analysis
  • DB Rimegepant vs DB Placebo · Mixed Models Analysis · p = =0.0006 (Tested in hierarchal order) · Lsm difference: -0.9 · 95% CI -1.36 to -0.38
SecondaryNumber of Participants With Any Adverse Events (AEs) by Worst Intensity in the DBT Phase.

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AE intensity included mild, moderate and severe, where Mild: usually transient and required only minimal treatment or therapeutic intervention. Event did not generally interfere with usual activities of daily living. Moderate: usually alleviated with additional specific therapeutic intervention. Event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to participant. Severe: interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Participants were counted once in each intensity category based on greatest intensity of unique adverse event preferred terms.

Time frame:
DBT Phase: From Day 1 to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events (AEs) by Worst Intensity in the DBT Phase.
ParticipantsDB RimegepantDB Placebo
Any AE186178
Mild AE132126
Moderate AE7765
Severe AE53
Moderate or Severe AE8065
Not Reported AE717
SecondaryNumber of Participants With Any AEs by Worst Intensity in the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AE intensity included mild, moderate and severe, where Mild: usually transient and required only minimal treatment or therapeutic intervention. Event did not generally interfere with usual activities of daily living. Moderate: usually alleviated with additional specific therapeutic intervention. Event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to participant. Severe: interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Participants were counted once in each intensity category based on greatest intensity of unique adverse event preferred terms.

Time frame:
OLE Phase: From Week 12 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Any AEs by Worst Intensity in the OLE Phase
ParticipantsDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Any AE121106
Mild AE7671
Moderate AE5252
Severe AE12
Moderate or Severe AE5253
Not Reported AE76
SecondaryNumber of Participants With Serious AEs (SAEs) in the DBT Phase

A serious adverse event (SAE) was any event that met any of the following criteria at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant and other important medical events.

Time frame:
DBT Phase: From Day 1 to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Serious AEs (SAEs) in the DBT Phase
ParticipantsDB RimegepantDB Placebo
Number of Participants With Serious AEs (SAEs) in the DBT Phase15
SecondaryNumber of Participants With SAEs in the OLE Phase

A SAE was any event that met any of the following criteria at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant and other important medical events.

Time frame:
OLE Phase: From Week 12 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With SAEs in the OLE Phase
ParticipantsDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Number of Participants With SAEs in the OLE Phase24
SecondaryNumber of Participants With AEs Leading to Study Drug Discontinuation in the DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with AEs leading to discontinuation of study drug were reported.

Time frame:
DBT Phase: From Day 1 to Week 12
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Drug Discontinuation in the DBT Phase
ParticipantsDB RimegepantDB Placebo
Number of Participants With AEs Leading to Study Drug Discontinuation in the DBT Phase63
SecondaryNumber of Participants With AEs Leading to Study Drug Discontinuation in the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with AEs leading to discontinuation of study drug were reported.

Time frame:
OLE Phase: From Week 12 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Drug Discontinuation in the OLE Phase
ParticipantsDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Number of Participants With AEs Leading to Study Drug Discontinuation in the OLE Phase33
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Abnormalities: DBT Phase

Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1. Only those Grade 3 or 4 laboratory tests with non-zero values in any of treatment arms are reported in this outcome measure.

Time frame:
DBT Phase: From Day 1 to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Abnormalities: DBT Phase
ParticipantsDB RimegepantDB Placebo
Neutrophils, low10
Glucose, high10
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Abnormalities: OLE Phase

Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to NCI CTCAE v5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1. Only those Grade 3 or 4 laboratory tests with non-zero values in any of treatment arms are reported in this outcome measure.

Time frame:
OLE Phase: From Week 12 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Abnormalities: OLE Phase
ParticipantsDB Rimegepant/ OL RimegepantDB Placebo/ OL Rimegepant
Platelets, low01
Glucose, high01
Glucose, low01
Sodium, high10
SecondaryPercentage of Participants With >= 50% Reduction From OP in the Number of Migraine Days Per Month (Regardless of Pain Intensity) Over the Entire DBT Phase (Weeks 1 to 12)

A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days and derived from data in the on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\])/(total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).

Time frame:
DBT phase (through Month 3 [Week 1 to 12])
Reported as:
Number · Percentage of participants
Percentage of Participants With >= 50% Reduction From OP in the Number of Migraine Days Per Month (Regardless of Pain Intensity) Over the Entire DBT Phase (Weeks 1 to 12)
Percentage of participantsDB RimegepantDB Placebo
Percentage of Participants With >= 50% Reduction From OP in the Number of Migraine Days Per Month (Regardless of Pain Intensity) Over the Entire DBT Phase (Weeks 1 to 12)27.5 (22.6 to 32.3)9.4 (6.2 to 12.6)
SecondaryMean Number of Acute Migraine-Specific Medication Days Per Month in Each Month and Over the Entire DBT Phase (Weeks 1 to 12)

An acute migraine-specific medication day was defined as any calendar day during which a participant took a migraine-specific acute migraine medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. The number of acute migraine-specific medication days per month were prorated to 28 days.

Time frame:
DBT phase Months 1, 2 and 3; overall DBT through Month 3 (Week 1 to 12)
Reported as:
Least squares mean · Medication Days per month
Mean Number of Acute Migraine-Specific Medication Days Per Month in Each Month and Over the Entire DBT Phase (Weeks 1 to 12)
Medication Days per monthDB RimegepantDB Placebo
Month 1: <=4 weeks3.3 (2.95 to 3.73)4.6 (4.18 to 5.09)
Month 2: >4 to <=8 weeks3.4 (2.96 to 3.79)4.8 (4.30 to 5.25)
Month 3: >8 to <=12 weeks3.5 (3.06 to 3.88)4.4 (3.94 to 4.90)
Overall DBT3.4 (3.03 to 3.76)4.6 (4.18 to 5.04)
SecondaryMean Change From Baseline in MIBS Scores at Weeks 4, 8, and 12 in the DBT Phase

MIBS was a 4-item self-administered questionnaire that measures: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Each item was rated on a 6-point scale as: don't know/ not applicable; never; rarely; some of the time; much of the time; most or all of the time. The MIBS score was the weighted sum of the item scores and ranged from 0 to 12. Higher scores indicated a greater impact of headaches on the participant's life between headache attacks.

Time frame:
DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in MIBS Scores at Weeks 4, 8, and 12 in the DBT Phase
Units on a scaleDB RimegepantDB Placebo
Week 4-1.3 (-1.66 to -1.04)-0.7 (-1.03 to -0.44)
Week 8-1.7 (-1.99 to -1.32)-1.1 (-1.45 to -0.80)
Week 12-1.9 (-2.24 to -1.52)-1.0 (-1.36 to -0.67)
SecondaryMean Change From Baseline in MSQ Domain Scores at Weeks 4, 8, and 12 in the DBT Phase

MSQ was a self-administered, 14-item instrument validated in 3 domains: role function-restrictive (7 items), role function-preventive (4 items), emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw domain scores are computed as a sum of item responses and rescaled to a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.

Time frame:
DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in MSQ Domain Scores at Weeks 4, 8, and 12 in the DBT Phase
Units on a scaleDB RimegepantDB Placebo
Restrictive role function domain score: Week 418.2 (16.17 to 20.13)12.7 (10.89 to 14.49)
Restrictive role function domain score: Week 820.7 (18.67 to 22.81)13.8 (11.72 to 15.80)
Restrictive role function domain score: Week 1221.1 (18.95 to 23.35)14.6 (12.48 to 16.68)
Preventive role function domain score: Week 414.0 (12.17 to 15.87)9.1 (7.27 to 10.94)
Preventive role function domain score: Week 816.0 (14.06 to 18.02)10.3 (8.39 to 12.26)
Preventive role function domain score: Week 1216.0 (13.95 to 18.00)10.7 (8.66 to 12.68)
Emotional function domain score: Week 415.4 (13.12 to 17.76)10.6 (8.22 to 12.89)
Emotional function domain score: Week 817.1 (14.64 to 19.54)11.4 (8.99 to 13.74)
Emotional function domain score: Week 1217.1 (14.70 to 19.56)11.0 (8.51 to 13.43)
SecondaryMean Change From Baseline in Migraine Functional Impact Questionnaire (MFIQ) Domain Scores in Each Month of the DBT Phase

MFIQ was a 26-item participant-report questionnaire. It is designed to measure the subjective impact of migraine on physical, social, and emotional functioning over 5 domains: physical function (5 items), usual activities (10 items), social function (5 items), emotional function (5 items) and overall impact on usual activities (16 items). Participants responded to items using a 5-point scale assigned scores from 1 to 5, with 5 representing the greatest burden. Each domain score was calculated as the sum of the item responses and rescaled to a 0 to 100 scale, with higher scores representing greater burden. The recall period was the past 7 days.

Time frame:
DBT Phase: Baseline (Day 1), Months 1, 2, and 3
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Migraine Functional Impact Questionnaire (MFIQ) Domain Scores in Each Month of the DBT Phase
Units on a scaleDB RimegepantDB Placebo
Physical function: Month 1-15.5 (-17.45 to -13.59)-8.8 (-10.52 to -7.15)
Physical function: Month 2-18.0 (-20.16 to -15.90)-11.3 (-13.29 to -9.26)
Physical function: Month 3-17.4 (-19.60 to -15.23)-11.7 (-13.76 to -9.57)
Usual activities: Month 1-14.8 (-16.58 to -13.03)-7.3 (-9.00 to -5.56)
Usual activities: Month 2-15.9 (-17.89 to -13.88)-9.0 (-11.04 to -6.99)
Usual activities: Month 3-15.5 (-17.52 to -13.50)-9.5 (-11.59 to -7.34)
Social function: Month 1-16.2 (-18.05 to -14.25)-9.2 (-11.12 to -7.34)
Social function: Month 2-17.4 (-19.63 to -15.25)-10.6 (-12.81 to -8.42)
Social function: Month 3-17.3 (-19.51 to -15.08)-11.7 (-13.91 to -9.41)
Emotional function: Month 1-15.4 (-17.54 to -13.28)-8.9 (-10.91 to -6.88)
Emotional function: Month 2-15.9 (-18.39 to -13.44)-10.1 (-12.48 to -7.75)
Emotional function: Month 3-15.5 (-18.01 to -12.97)-10.7 (-13.25 to -8.19)
Overall impact on usual activities: Month 1-16.3 (-18.29 to -14.39)-9.1 (-10.93 to -7.25)
Overall impact on usual activities: Month 2-18.4 (-20.53 to -16.23)-10.1 (-12.31 to -7.87)
Overall impact on usual activities: Month 3-17.8 (-19.99 to -15.68)-11.9 (-14.10 to -9.71)
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI) - Migraine Absenteeism Scores at Weeks 4, 8, and 12 in the DBT Phase

The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The absenteeism score was calculated from Q2 and Q4 for participants who responded "yes" to Q1 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.

Time frame:
DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Work Productivity and Activity Impairment (WPAI) - Migraine Absenteeism Scores at Weeks 4, 8, and 12 in the DBT Phase
Units on a scaleDB RimegepantDB Placebo
Absenteeism: Week 4-3.4 (-5.02 to -1.88)-2.0 (-4.00 to -0.09)
Absenteeism: Week 8-4.1 (-6.17 to -2.10)-2.0 (-3.87 to -0.19)
Absenteeism: Week 12-3.0 (-4.96 to -0.98)-1.4 (-3.83 to 0.98)
SecondaryChange From Baseline in WPAI - Migraine Presenteeism Scores at Weeks 4, 8, and 12 in the DBT Phase

The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The presenteeism score was calculated using Q5 for participants who responded "yes" to Q1 and had Q4\>0 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.

Time frame:
DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in WPAI - Migraine Presenteeism Scores at Weeks 4, 8, and 12 in the DBT Phase
Units on a scaleDB RimegepantDB Placebo
Presenteeism: Week 4-16.8 (-20.54 to -13.14)-11.8 (-15.24 to -8.30)
Presenteeism: Week 8-19.8 (-23.63 to -16.07)-11.8 (-15.41 to -8.18)
Presenteeism: Week 12-18.8 (-22.38 to -15.20)-10.9 (-14.69 to -7.04)
SecondaryChange From Baseline in WPAI - Migraine Work Productivity Loss Scores at Weeks 4, 8, and 12 in the DBT Phase

The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The work productivity loss score was calculated using Q2, Q4, and Q5 for participants who responded "yes" to Q1 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.

Time frame:
DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in WPAI - Migraine Work Productivity Loss Scores at Weeks 4, 8, and 12 in the DBT Phase
Units on a scaleDB RimegepantDB Placebo
Work productivity loss: Week 4-17.4 (-21.28 to -13.60)-11.9 (-15.45 to -8.28)
Work productivity loss: Week 8-20.8 (-24.83 to -16.74)-11.9 (-15.59 to -8.12)
Work productivity loss: Week 12-19.1 (-22.94 to -15.24)-11.5 (-15.51 to -7.51)
SecondaryChange From Baseline in WPAI - Migraine Activity Impairment Scores at Weeks 4, 8, and 12 in the DBT Phase

The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The activity impairment score was calculated using Q6 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.

Time frame:
DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in WPAI - Migraine Activity Impairment Scores at Weeks 4, 8, and 12 in the DBT Phase
Units on a scaleDB RimegepantDB Placebo
Activity impairment: Week 4-18.5 (-21.56 to -15.47)-14.4 (-17.37 to -11.52)
Activity impairment: Week 8-23.0 (-26.18 to -19.80)-15.7 (-18.61 to -12.70)
Activity impairment: Week 12-21.6 (-24.63 to -18.63)-14.0 (-17.08 to -10.82)
SecondaryMean Change From Baseline in Patient Global Assessment (PGA) Score in Each Month of the DBT Phase

The PGA scale was a single item assessment that measured the participant's overall assessment of migraine on a 5-point scale as: (1) very good: asymptomatic and no limitation of normal activities; (2) good: mild symptoms and no limitation of normal activities; (3) fair: moderate symptoms and limitation of some normal activities; (4) poor: severe symptoms and inability to carry out most normal activities; (5) very poor: very severe symptoms which are intolerable and inability to carry out all normal activities. Lower scores indicated fewer symptoms and less disability to carry out normal activities.

Time frame:
DBT Phase: Baseline (Day 1), Months 1, 2, and 3
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Patient Global Assessment (PGA) Score in Each Month of the DBT Phase
Units on a scaleDB RimegepantDB Placebo
Month 1-0.1 (-0.19 to -0.08)0.0 (-0.08 to 0.02)
Month 2-0.2 (-0.22 to -0.10)0.0 (-0.11 to 0.01)
Month 3-0.2 (-0.22 to -0.10)0.0 (-0.11 to 0.01)

Adverse events

Collected over Baseline up to 2 weeks after last visit in the last treatment phase (treatment period for DBT: From Day 1 to Week 12 and for OLE: After Week 12 to Week 24; Follow-up: 2 weeks after last visit in the last treatment phase). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Rimegepant: DBT Phase0/328 (0%)1/328 (0.3%)43/328 (13.1%)
DB Placebo: DBT Phase0/324 (0%)5/324 (1.5%)51/324 (15.7%)
DB Rimegepant/ OL Rimegepant: OLE Phase0/301 (0%)2/301 (0.7%)22/301 (7.3%)
DB Placebo/ OL Rimegepant: OLE Phase0/294 (0%)4/294 (1.4%)12/294 (4.1%)
DB Rimegepant/ OL Rimegepant: Follow-up Phase0/308 (0%)1/308 (0.3%)1/308 (0.3%)
DB Placebo/ OL Rimegepant: Follow-up Phase0/296 (0%)2/296 (0.7%)2/296 (0.7%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventDB Rimegepant: DBT PhaseDB Placebo: DBT PhaseDB Rimegepant/ OL Rimegepant: OLE PhaseDB Placebo/ OL Rimegepant: OLE PhaseDB Rimegepant/ OL Rimegepant: Follow-up PhaseDB Placebo/ OL Rimegepant: Follow-up Phase
Immune thrombocytopeniaBlood and lymphatic system disorders0/3280/3240/3011/2940/3080/296
MeningitisInfections and infestations0/3280/3240/3011/2940/3080/296
IIIrd nerve paralysisNervous system disorders0/3280/3240/3011/2940/3080/296
MigraineNervous system disorders0/3280/3240/3011/2940/3080/296
Pneumonia pneumococcalInfections and infestations0/3280/3240/3010/2940/3081/296
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3280/3240/3010/2940/3081/296
Superficial spreading melanoma stage IINeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3280/3241/3010/2940/3080/296
Renal colicRenal and urinary disorders0/3280/3241/3010/2940/3080/296
ArrhythmiaCardiac disorders0/3280/3240/3010/2941/3080/296
AnaemiaBlood and lymphatic system disorders0/3281/3240/3010/2940/3080/296
Most frequent other events
Most frequent other events
EventDB Rimegepant: DBT PhaseDB Placebo: DBT PhaseDB Rimegepant/ OL Rimegepant: OLE PhaseDB Placebo/ OL Rimegepant: OLE PhaseDB Rimegepant/ OL Rimegepant: Follow-up PhaseDB Placebo/ OL Rimegepant: Follow-up Phase
NasopharyngitisInfections and infestations29/32846/32422/30112/2941/3082/296
Back painMusculoskeletal and connective tissue disorders17/3287/3245/3013/2940/3080/296

Baseline characteristics

DBT safety analysis set (SAS): enrolled participants who took greater than or equal to (\>=)1 dose of DB study drug (rimegepant or placebo).

Age, Continuous
Age, Continuous(Years)DB Rimegepant/ OL RimegepantDB Placebo/ OL RimegepantTotal
Mean42.68 ± 10.5041.98 ± 11.1442.33 ± 10.82
Sex: Female, Male
Sex: Female, Male(Participants)DB Rimegepant/ OL RimegepantDB Placebo/ OL RimegepantTotal
Female289272561
Male395291
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DB Rimegepant/ OL RimegepantDB Placebo/ OL RimegepantTotal
Hispanic or Latino448
Not Hispanic or Latino141630
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DB Rimegepant/ OL RimegepantDB Placebo/ OL RimegepantTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American314
White151833
More than one race000
Unknown or Not Reported000
08

Study locations

111 sites
  • Clinical Research Institute
    Los Angeles, California 90048, United States
  • California Neuroscience Research, LLC
    Sherman Oaks, California 91403, United States
  • Ki Health Partners LLC, dba New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Sandhill Research, LLC d/b/a Accel Research Sites Network-Edgewater Clinical Research Unit
    Edgewater, Florida 32132, United States
  • Wr-Msra,Llc
    Lake City, Florida 32055, United States
  • AppleMed Research Group, LLC
    Miami, Florida 33126, United States
  • Sensible Healthcare LLC
    Ocoee, Florida 34761, United States
  • Sandhill Research, LLC d/b/a Accel Research Sites Network - Ormond Clinical Research Unit
    Ormond Beach, Florida 32174, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Community Clinical Research Network, Inc.
    Marlborough, Massachusetts 01752, United States
  • Michigan Headache & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Rochester Medical Group
    Rochester Hills, Michigan 48307, United States
  • Clinvest Research, LLC
    Springfield, Missouri 65807, United States
  • St Charles Clinical Research
    Weldon Spring, Missouri 63304, United States
  • Wr-Crcn, Llc
    Las Vegas, Nevada 89118, United States
  • Albuquerque Clinical Trials. Inc.
    Albuquerque, New Mexico 87102, United States
  • DiGiovanna Institute for Medical Education And Research
    North Massapequa, New York 11758, United States
  • Headache Wellness Center, PC
    Greensboro, North Carolina 27405, United States
  • Synexus Clinical Research US, Inc. - Anderson
    Anderson, South Carolina 29621, United States
  • Alliance for Multispecialty Reseach, LLC
    Knoxville, Tennessee 37909, United States
  • Red Star Research, LLC
    Lake Jackson, Texas 77566, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • USC Clinical Trials Sunshine Coast
    Sippy Downs, Queensland 4556, Australia
  • Medical University Innsbruck
    Innsbruck, Tyrol 6020, Austria
  • Klinikum Klagenfurt am Wörthersee
    Klagenfurt, 9020, Austria
  • UZ Brussel
    Jette, Brussels Capital 1090, Belgium
  • GZA Ziekenhuizen
    Antwerp, 2610, Belgium
  • AZ Sint-Jan Brugge-Oostende AV
    Bruges, 8000, Belgium
  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
  • Clinique de la Citadelle
    Liège, 4000, Belgium
  • Cabinet Privé Dr. Simona Sava
    Saint Nicolas Province de Liège, 4420, Belgium
  • Aggarwal and Associates Limited
    Brampton, Ontario L6T 0G1, Canada
  • NeuPath Centre for Pain and Spine
    Brampton, Ontario L6V 1C2, Canada
  • Centre de Recherche Saint-Louis/Clinique Neuro-Levis
    Lévis, Quebec G6W0M5, Canada
  • ALPHA Recherche Clinique
    Québec, Quebec G3K 2P8, Canada
  • ALPHA Recherche Clinique
    Québec, G2J 0C4, Canada
  • Bispebjerg Hospital
    Copenhagen NV, Capital Region 2400, Denmark
  • Danish Headache Center
    Glostrup Municipality, Capital Region 2600, Denmark
  • University Hospital of Southern Denmark
    Esbjerg, DK-6700, Denmark
  • Hospitalsenhed Midt
    Viborg, DK-8800, Denmark
  • Terveystalo Ruoholahti
    Helsinki, Uusimaa 00180, Finland
  • Terveystalo Tampere
    Tampere, 33100, Finland
  • Terveystalo Pulssi
    Turku, 20100, Finland
  • Schmerz- und Palliativzentrum Göppingen
    Göppingen, Baden-Wurttemberg 73033, Germany
  • Zentrum für klinische Forschung
    Bad Homburg, Hesse 61350, Germany
  • Synexus Clinical Research GmbH Synexus Frankfurt Clinical Research Centre
    Frankfurt am Main, Hesse 60313, Germany
  • Kopfschmerzzentrum Frankfurt
    Frankfurt am Main, Hesse 65929, Germany
  • Intermed GmbH
    Wiesbaden, Hesse 65189, Germany
  • Studienzentrum Nordwest
    Westerstede, Lower Saxony 26655, Germany
  • Synexus - Prüfzentrum Leipzig
    Leipzig, Saxony 04103, Germany
  • Synexus - Prüfzentrum Berlin
    Berlin, 12672, Germany
  • Neuropoint GmbH
    Ulm Baden-Wuerttemberg, 89073, Germany
  • IRCCS Fondazione Istituto Neurologico Nazionale C. Mondino
    Pavia, Lombardy 27100, Italy
  • IRCCS Ospedale San Raffaele
    Milan, MI 20132, Italy
  • AOU Luigi Vanvitelli
    Naples, Naples 80134, Italy
  • IRCCS San Raffaele
    Rome, Rome/lazio 00163, Italy
  • SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
    Florence, 50134, Italy
  • IRCCS Fondazione Besta
    Milan, 20133, Italy
  • University Modena e Reggio Emilia
    Modena, 41124, Italy
  • Phylasis Clinicas Research S. de R.L. de C.V.
    Cuautitlán Izcalli, State of Mexico 54769, Mexico
  • Clinical Research Institute S.C.
    Tlalnepantla, State of Mexico C.P. 54055, Mexico
  • Medical Care and Research S.A. de C.V.
    Mérida, Yucatán CP. 97070, Mexico
  • Centro de Investigación Médica de Aguascalientes (CIMA)
    Aguascalientes, 20116, Mexico
  • Clinstile, SA de CV
    Mexico City, CDMX 06700, Mexico
  • Operadora Unidad de Investigación En Salud de Chihuahua, Sa de Cv
    Mexico City, CP 14050, Mexico
  • Centrum Medyczne Neuromed
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-163, Poland
  • MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak
    Wroclaw, Lower Silesian Voivodeship 52-210, Poland
  • Twoja Przychodnia Nowosolskie Centrum Medyczne
    Nowa Sól, Lubusz Voivodeship 67-100, Poland
  • Centermed Kraków Sp. Z o.o.
    Krakow, Malopolska 31-530, Poland
  • Concept Medica
    Warsaw, Masovian Voivodeship 00-773, Poland
  • Dr Sekowska Leczenie Bolu
    Warsaw, Masovian Voivodeship 01-018, Poland
  • MICS Centrum Medyczne Damiana Walbrzyska
    Warsaw, Masovian Voivodeship 02-739, Poland
  • Instytut Zdrowia
    Oświęcim, Małopolska 32-600, Poland
  • Centrum Medyczne Pratia Katowice
    Katowice, 40-081, Poland
  • Vita Longa Sp. Z o.o.
    Katowice, 40-748, Poland
  • MICS Centrum Medyczne Szczecin
    Szczecin, 70-784, Poland
  • MTZ Clinical Research Powered by Pratia
    Warsaw, 02-172, Poland
  • Premium Clinic Wrocław
    Wroclaw, 50-414, Poland
  • Centrum Medyczne OPOROW
    Wroclaw, 52-416, Poland
  • Centrum Leczenia Bolu dr n med Lukasz Kmieciak
    Lodz, Łódź Voivodeship 91-363, Poland
  • Hospital Universitario de Elda
    Elda, Alicante 03600, Spain
  • Hospital Clinic de Barcelona Plato Headquarters
    Barcelona, 08006, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario de La Princesa
    Madrid, 28006, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • Hospital Universitario Ruber Juan Bravo
    Salamanca, 28006, Spain
  • University Hospital Marqués de Valdecilla
    Santander, 39008, Spain
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
  • Virgen del Rocio University Hospital
    Seville, 41013, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Consorcio Hospital General Universitario
    Valencia, 46014, Spain
  • Hospital Clinico Universitario de Valladolid
    Valladolid, 47010, Spain
  • CTC Solna
    Solna, Stockholms LÄN [se-01] 171 64, Sweden
  • CTC MTC
    Uppsala, Uppsala LÄN [se-03] 752 37, Sweden
  • Carlanderska Hospital
    Gothenburg, 40545, Sweden
  • Skåneuro Privatmottagning
    Lund, 222 22, Sweden
  • Hälsoklustret
    Stockholm, 112 39, Sweden

Showing the first 100 of 111 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pozo-Rosich P, Gien Lopez JA, Lisewski P, Aslan AN, Seehra H, Thiry A, Abraham L, Ramirez LM, Fountaine R, Fullerton T. Does rimegepant prevent migraine attacks in people who have not found other treatments taken by mouth (orally) to work well? A plain language summary of clinical study findings. Pain Manag. 2026 Jun;16(6):539-550. doi: 10.1080/17581869.2026.2646702. Epub 2026 Apr 28. PubMed 42047365 ↗
  • Pozo-Rosich P, Lopez JAG, Lisewski P, Aslan AN, Seehra H, Thiry A, Abraham L, Ramirez LM, Fountaine R, Fullerton T. A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications. Cephalalgia. 2025 Nov;45(11):3331024251391378. doi: 10.1177/03331024251391378. Epub 2025 Nov 18. PubMed 41255098 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Mar 2025, 28 months.

Results were first posted in May 2026, 1 year 1 month after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 28 months is close to that.

Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Aug 26, 2022
StartActual
Nov 7, 2022
Primary completionActual
Mar 31, 2025
CompletionActual
Jul 8, 2025
Results first posted
May 22, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05518123
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 26, 2022
Start date
Nov 7, 2022
Primary completion
Mar 31, 2025
Completion
Jul 8, 2025
Results posted
May 22, 2026
Last update
May 22, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion